Shaman AM, Bain SC, Bakris GL, et al. - In type 2 diabetes (T2D) patients, kidney-protective effects were conferred by semaglutide/liraglutide; such impacts seemed to be more pronounced in those with pre-existing chronic kidney disease.

• By analyzing pooled (N=12,637) and by-trial data from SUSTAIN 6 (N=3297) and LEADER (N=9,340), experts examined the impact of once-weekly semaglutide and once-daily liraglutide on renal outcomes in T2D patients.

• Pooled analysis revealed albuminuria reduction by 24%, from baseline to 2 years post-randomization, in those who received semaglutide/liraglutide vs placebo.

• By-trial data analyses also showed significant reductions, the largest being with semaglutide 1.0 mg: 33% at 2 years.

• Risk of persistent 40% and 50% estimated glomerular filtration rate (eGFR) reductions was significantly reduced with semaglutide/liraglutide vs placebo, with hazard ratios 0.86 and 0.80, respectively.

• In patients with baseline eGFR 30−<60mL/min/1.73m ² , an increase was evident in the probability of persistent reduction for all thresholds, ranging from a hazard ratio 0.71 for 30% reduction to 0.54 for 57% reduction.